Methods of using chimeric coiled-coil molecule

Abstract

The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.

1 . A coiled coil chimeric molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand. 
     
     
         2 . A method of treating an ischemic disease comprising administering to a person in need thereof an effective amount of the molecule according to  claim 1 . 
     
     
         3 . The method according to  claim 2 , wherein the coiled coil domain comprises a domain belonging to a protein belonging to matrix protein family, transcription factor family, growth factor family or secretory protein family. 
     
     
         4 . The method according to  claim 3 , wherein the coiled coil domain is from cartilage matrix protein or cartilage oligomeric matrix protein. 
     
     
         5 . The method according to  claim 2 , wherein the receptor binding domain binds to Tie1 or Tie2. 
     
     
         6 . The method according to  claim 2 , wherein the ligand is a cytokine, hormone or growth factor. 
     
     
         7 . The method of  claim 6 , wherein the ligand is angiopoietin-1. 
     
     
         8 . The method of  claim 7 , wherein the chimeric coiled coil molecule is COMP-Ang1. 
     
     
         9 . The method according to  claim 2 , wherein the ischemic disease is of the heart, limb, brain, penis, stomach or kidney. 
     
     
         10 . The method according to  claim 2 , wherein the chimeric coiled coil molecule is administered in its protein form. 
     
     
         11 . The method according to  claim 10 , wherein the protein is in form for topical administration. 
     
     
         12 . The method according to  claim 2 , wherein the chimeric coiled coil molecule is administered in gene construct form within a delivery vehicle. 
     
     
         13 . The method according to  claim 12 , wherein the delivery vehicle is a virus. 
     
     
         14 . The method according to  claim 13 , wherein the delivery vehicle is adenovirus. 
     
     
         15 - 17 . (canceled) 
     
     
         18 . A method for treating vascular leakage comprising administering to a person in need thereof an effective amount of the molecule according to  claim 1 . 
     
     
         19 . The method according to  claim 18 , wherein the vascular leakage is due to sepsis, diabetic retinopathy, brain edema, excessive hemorrhagia, menorrhagia or nasal bleeding. 
     
     
         20 - 21 . (canceled) 
     
     
         22 . A method for treating myocardial infarction comprising administering to a person in need thereof an effective amount of the molecule according to  claim 1 .